Skip to main content
. 2013 Jul 9;2013(7):CD006910. doi: 10.1002/14651858.CD006910.pub2

NCT01666444.

Trial name or title VTX‐2337 and pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
Methods Phase II double blind multicentre RCT
Participants 210 women with PR ROC
Interventions VTX‐2337 + PLD versus PLD + placebo
Outcomes Primary: OS
Secondary: PFS, toxicity, ORR, DCR
Starting date Aug 2012
Contact information Bradley Monk: bradley.monk@chw.edu
Notes End Date: Mar 2016